Literature DB >> 11686321

The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.

L O Mosnier1, T Lisman, H M van den Berg, H K Nieuwenhuis, J C Meijers, B N Bouma.   

Abstract

TAFI (thrombin activatable fibrinolysis inhibitor) down regulates fibrinolysis after activation by relatively high concentrations of thrombin generated during coagulation via thrombin mediated factor XI activation and subsequent activation of the intrinsic pathway. It is this secondary burst of thrombin that is severely diminished in haemophilia A, a deficiency of coagulation factor VIII. We therefore investigated the role of TAFI in haemophilia A by measuring the clot lysis times of tissue factor induced fibrin formation and tPA mediated fibrinolysis. In haemophilia A plasma clot lysis times were normal at relatively high tissue factor concentrations but severely decreased at moderate to low tissue factor concentrations, indicating that the thrombin generation via the extrinsic pathway was insufficient to activate TAFI. Addition of factor VIII, TAFI or thrombomodulin restored the clot lysis times at low tissue factor concentrations. This confirms the hypothesis that the bleeding disorder in haemophilia A is not merely a defect in the initial clot formation but is in fact a triple defect: reduced thrombin formation via the extrinsic pathway at low tissue factor concentrations, a reduced secondary burst of thrombin generation via the intrinsic pathway and a defective down regulation of the fibrinolytic system by the intrinsic pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686321

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

2.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Authors:  Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier
Journal:  Thromb Haemost       Date:  2015-10-15       Impact factor: 5.249

3.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

4.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

5.  Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Authors:  R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen
Journal:  J Thromb Haemost       Date:  2018-06-21       Impact factor: 5.824

6.  Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.

Authors:  M Zucker; U Seligsohn; O Salomon; A S Wolberg
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

7.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27

Review 8.  Thrombin generation, fibrin clot formation and hemostasis.

Authors:  Alisa S Wolberg; Robert A Campbell
Journal:  Transfus Apher Sci       Date:  2008-02-20       Impact factor: 1.764

Review 9.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

10.  Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.

Authors:  Fabrizio Semeraro; Concetta T Ammollo; Nicola Semeraro; Mario Colucci
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.